Aristotle University Of Thessaloniki (AUTH)
Μελέτη με κυτταρομετρία ροής των νεότερων προγνωστικών δεικτών στα χρόνια Β-λεμφοϋπερπλαστικά νοσήματα
Abstract
dc:descriptionIntroduction: Β-Lymphoproliferative Disorders (B-LPDs) are clonal B cell disorders. Chronic Lymphocytic Leukemia (CLL) is the most common leukemia in the Western world. CLL’s clinical course and prognosis are extremely variable. Some patients live for decades with no need for treatment, whereas others have a rapidly aggressive clinical course. Although clinical stages remain the basis for assessing prognosis in CLL, newer prognostic factors are necessary to provide prognosis, especially for early stage disease patients. IgVH mutations and cytogenetic abnormalities offer independent prognostic value but the methods used to determine them are available in a limited number of centres because they are expensive, time consuming and technically demanding. Potential newer prognostic markers such as CD38, proteins ZAP-70 and p53 which are relatively easy to determine by Flow Cytometry (FC) are under investigation. FC is relatively simple and rapidly obtained in most diagnostic laboratories for B-LPD diagnosis but regarding disease prognosis, FC needs validation and standardization. PURPOSE: Validation and standardization of FC regarding CD38, ZAP-70 and p53 determination. Study of the probability for FC to surrogate Immunohistochemistry regarding ZAP-70 protein’s determination and del17p determined by FISH by the determination of p53 protein regarding B-LPD patients. Validation of CD38, ZAP-70 and p53 prognostic significance regarding CLL patients. Identification of newer prognostic factors of independent prognostic value, in order to assess the need for therapy regarding CLL patients, especially early stage CLL patients. This will assist in identifying low risk patients who will develop progressive disease and may benefit from early and/or more intensive treatment (risk stratification). Materials and methods: 100 consecutive B-LPD patients from a single institution were enrolled in the study and were followed for 1-216 months (median 35 months), 60 (60%) men, aged 40-88 years (median 68 years). Patients were divided in two groups. Group A: 80 CLL patients, 52 (65%) men, median diagnosis age 67 years, median follow-up time 37 months. 54 (67,5%) patients, which is the majority among CLL patients, were stage 0, according to the Rai staging system (low risk patients). Group B: 20 B-LPD patients, 8 (40%) men, median diagnosis age 74 years, median follow-up time 25,5 months. High-risk genomic aberrations such as del17p were analyzed by Fluorescence in Situ Hybridization (FISH), ZAP-70 protein was determined by Immunohistochemistry and Flow Cytometry (FC), CD38 and p53 expression by triple-colour FC both in peripheral blood and bone marrow aspiration. Two different FC protocols were evaluated regarding intracellular antigens (ZAP-70 and p53 proteins). LDH and β2-microglobulin were also determined. RESULTS: We found high CD38 expression in 56 (56%) patients, high ZAP-70 expression in 62 (62%) and high p53 expression in 28 (29,9%) patients regarding peripheral blood measurements. Using Spearmann coefficient we found positive correlation between peripheral blood and bone marrow aspiration results for all the three markers (p<0,0001). k coefficient of agreement and Mc Nemars and Bowkers test revealed positive correlation between FC and Immunohistochemistry regarding ZAP-70 determination and between FISH and FC regarding the determination of del17p and p53 protein, respectively (p=1). The optimum cut-off point for FC was determined using ROC curves and was found to be 10%, 20% and 12,5% for CD38, ZAP-70 and p53, respectively. Using MANOVA fit for CD38 and Wilcoxon-Sign Rank test for ZAP-70 we found that both markers were not stable during the course of the disease (p=0,017, p=0,003, respectively). The rest of the study concerns CLL patients (Group A). No correlations were determined in Group B because of the small number of patients. Using χ² we found that high CD38, ZAP-70 or p53 expression was positively related to the need for therapy (p=0,025, p=0,013 and p<0,001). But using ROC curves we found that only CD38 and p53 were of independent prognostic significance. In multivariate analysis p53 was identified as independent prognostic factor, indicating that p53 alone can predict the need for therapy in CLL. Independent prognostic significance was also established for clinical staging, LDH and β2-microglobulin (p=0,002, p=0,025 and p<0,001). No correlation was found between the three markers and the Time To First Treatment (TTT) (Log-rank test p=0,545, p=0,102 and p=0,646) or relapsed disease (χ² p=0,930, p=0,360 and p=0,475). Finally using χ² we found that CD38, p53 and their combination predict the need for therapy for the sensitive and numerous group consisted from low risk CLL patients (p=0,02, p=0,02 and p=0,005). CONCLUSIONS: It is in our opinion that FC represents a very good tool in order to determine CD38 and ZAP-70 and p53 proteins both in peripheral blood and bone marrow aspiration. Our improved protocol can be incorporated into the B-LPDs diagnostic protocol. FC surrogates Immunohistochemistry regarding ZAP-70 determination and del17p determined by FISH with the determination of p53 protein. CD38 and ZAP-70 expression determined by FC failed to maintain stable during the course of CLL, so we propose their determination more than once and especially when CD38 and ZAP-70 negative patients develop progressive disease. The optimum cut-off points that we determined for CD38 and ZAP-70 agree with those given by international studies and ERIC (European Research Initiative on CLL). The optimum cut-off point proposed for p53 protein is different than the cut-off point used internationally and has to be evaluated in larger cohorts of patients. CD38, ZAP-70 and p53 proteins determined by FC are of independent prognostic value concerning the need for treatment and add to the classical assessment of CLL provided by staging systems, LDH and β2-microglobulin, right after diagnosis. In multivariate analysis, p53 alone can predict the need for therapy in CLL. CD38, p53 and their combination distinguished early-stage patients who will need therapy from those whose disease will remain indolent and will not benefit from early treatment. Due to the small number of patients we could not establish any correlation between the three prognostic factors and TTT. Finally, due to limited follow up time we could not establish any correlation between CD38, ZAP-70, p53 and relapsing disease or survival.
Degree
thesis:*- Grantor dc:publisher
- Aristotle University Of Thessaloniki (AUTH)
- Year dc:date
- 2012
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Tsioni, Konstantina
- Τσιώνη, Κωνσταντίνα
Subjects
dc:subject × 20- Κυτταρομετρία ροής
- Χρόνια Β λεμφοϋπερπλαστικά νοσήματα
- Χρόνια λεμφικυτταρική λευχαιμία
- Πρωτεΐνη ZAP-70
- Πρωτεΐνη p53
- Αντιγόνο CD38
- Προγνωστικοί δείκτες
- ΧΛΛ
- Flow cytometry
- Chronic B lymphoprolyferative disorders
- Chronic lymphocytic leykemia
- ZAP-70
- p53
- CD 38
- Prognostic factors
- CLL
- Επιστήμες Μηχανικού και Τεχνολογία
- Βιοϊατρική Μηχανική
- Engineering and Technology
- Medical Engineering
Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/27617